Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

NEW DRUGS

FDA Approved Fyarro for Malignant Perivascular Epithelioid-Cell Tumor

JHOP - December 2021 Vol 11, No 6 - FDA Oncology Update
Download PDF

On November 22, 2021, the FDA approved sirolimus protein-bound particles for injectable suspension (albumin-bound [Fyarro; Aadi Bioscience]) for adults with locally advanced, unresectable or metastatic malignant perivascular epithelioid-cell tumor (PEComa), a rare type of mesenchymal tumors that can occur in any body site.

This FDA approval was based on a multicenter, single-arm clinical trial of 31 patients with locally advanced, unresectable or metastatic malignant PEComa. Patients received sirolimus protein-bound particles on days 1 and 8 of each 21-day cycle, until disease progression or unacceptable adverse events.

The main end points were overall response rate (ORR) and duration of response (DOR). The ORR was 39% (95% confidence interval [CI], 22%-58%), which included 2 patients with complete responses. The median DOR was not reached (95% CI, 6.5 months-not estimable). Of the 39% of patients who had a response, 67% had a response lasting >12 months, and 58% had a response lasting >24 months.

The most common (≥30%) adverse events were stomatitis, fatigue, rash, infection, nausea, edema, diarrhea, musculoskeletal pain, decreased weight, decreased appetite, cough, vomiting, and dysgeusia. The most common (≥6%) grade 3 or 4 laboratory abnormalities were decreased lymphocytes, increased glucose, decreased potassium, decreased phosphate, decreased hemoglobin, and increased lipase.

The recommended dosage is 100 mg/m2, administered as an intravenous infusion over 30 minutes on days 1 and 8 of each 21-day cycle, until disease progression or unacceptable side effects.

Related Items
Pluvicto FDA Approved for PSMA-Positive Metastatic Prostate Cancer
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Keytruda Monotherapy FDA Approved for Endometrial Carcinoma with a Biomarker
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Kimmtrak, a Bispecific CD3 T-Cell Engager, First FDA-Approved Drug for Unresectable or Metastatic Uveal Melanoma
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in FDA Oncology Update
Orencia First Drug FDA Approved for the Prevention of Acute Graft-versus-Host Disease
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in FDA Oncology Update
Keytruda Now Approved for the Adjuvant Treatment of Stage IIB/IIC Melanoma
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in FDA Oncology Update
Rituximab plus Chemotherapy FDA Approved for Several Pediatric Hematologic Malignancies
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in FDA Oncology Update
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.